Business
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.This clinical trial aims to complete the enrollment of 30
About this update from Ainos, Inc.
[{"type":"text","content":"The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025. SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified healthcare company focused on novel AI-powered point-of-care testing (\"POCT\") and low-dose interferon therapeutics (\"VELDONA\"), today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis (\"FCGS\"), a serious and painful chronic cat oral disease characterized by inflammation or abnormal proliferation in the oral cavity. Dosing of the first subject is expected to occur on July 26, 2024.This animal clinical study is a randomized, double-blind, parallel, single-center, multiple-dose oral drug trial designed to evaluate the safety, tolerability, and efficacy of low-dose oral interferons in the treatment of FCGS. The clinical site in Taiwan is expected to enroll 30 subjects.This study builds on the animal health research of Ainos' VELDONA®, a low-dose oral interferon alpha (\"IFNα\") formulation that was initially approved by the Texas Department of Health in 1985 for treating feline leukemia in cats and canine parvovirus in dogs. The trial aims to complete the enrollment of 30 subjects by the end of 2024 and to finalize the trial report in the first quarter of 2025. If the results meet expectations, Ainos will initiate the next phase involving an application to a clinical field trial for an animal drug certificate from the Animal and Plant Health Inspection Agency under Taiwan's Ministry of Agriculture.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and CEO of Ainos, commented, \"We are pleased to announce the enrollment of the first subject in the clinical trial, with dosing scheduled for July 26, 2024, marking an important milestone in the animal drug development process of VELDONA®. Initiating this clinical trial emphasizes our relentless efforts to advance innovative treatment options for cats with FCGS. Furthermore, we are also committed to fully leveraging our VELDONA® platform to develop a diversified portfolio of products for various therapeutic areas.\"According ...